FDA approval updates for fam-trastuzumab deruxtecan were reported, indicating the agency cleared two separate new indications for the antibody-drug conjugate. The update was circulated via a submission reference rather than a full release in the provided excerpt. For biotech and pharma decision-makers, incremental label expansion can affect standard-of-care positioning, sequencing with other HER2-directed therapies, and demand forecasting across oncology practices. Key details on indications and trial bases were not included in the excerpt, but the regulatory action itself signals continued movement of the ADC’s clinical footprint.